

Discovery Services

Certificate of Analysis

MLCK, active (Recombinant enzyme expressed in Sf21 insect cells) Item # 14-638, 14-638-K, 14-638M Parent Lot # 1611522

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: *N*-terminal 6His. tagged, recombinant, human MLCK, amino acids 1425–1771, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 88.9% by SDS-PAGE and Coomassie blue staining. MW = 43.7kDa.

Specific Activity (Parent lot# 1611522): 224U/mg, where one unit of MLCK activity is defined as 1nmol phosphate incorporated into 250µM (KKLNRTLSFAEPG) per minute at 30°C with a final ATP concentration of 100µM. **Formulation: 1.76mg/ml** of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 6 months from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

FOR IN VITRO RESEARCH USE ONLY NOT FOR USE IN HUMANS OR ANIMALS

Quality Control Testing

<u>Kinase Assay</u>: 19.2–53ng of this lot of enzyme phosphorylated 250 μ M (KKLNRTLSFAEPG) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



Eurofins Pharma Discovery Services UK Limited Gemini Crescent Dundee Technology Park DUNDEE DD2 1SW United Kingdom <u>MS Tryptic Fingerprint:</u> Confirmed identity as MLCK with the translated native sequence listed on page three.



T +44 (0)1382 561600 F +44 (0)1382 561601 www.eurofins.com/pharmadiscovery



Discovery Services

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer: 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- (KKLNRTLSFAEPG): Use at a final concentration of 250µM. Make a 2.5mM stock. Use 2.5µl of stock solution per assay point.
- 3. MLCK, active: Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 19.2–53ng per assay point.
- 4. $[\gamma^{-33}P]$ ATP: 2.5 x magnesium acetate/ $[\gamma^{-33}P]$ ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added $[\gamma^{-33}P]$ ATP (specific activity approximately 500 800cpm/pmol as required.)
- CaCl₂: Use at a final concentration of 0.5mM. Make a 5mM stock. Use 2.5µl of stock solution per assay point.
- Calmodulin: Use at a final assay concentration of 1µM. Make a 0.3mg/ml stock solution. Use 1.33µl of stock per assay point.

Assay Procedure (96 well plate format):

- 1. Add 5µl of 5 x reaction buffer per assay to wells.
- 2. Add 2.5µl of (KKLNRTLSFAEPG).
- 3. Add 2.5µl (19.2–53ng) MLCK, active.
- 4. Add 2.5µl of 5mM CaCl₂.
- 5. Add 1.33µl of 0.3mg/ml calmodulin.
- 6. Add 1.17 μ l of dH₂O.
- 7. Add 10µl of diluted [γ -³³P]ATP mixture.
- 8. Incubate for 10 minutes at 30°C.
- 9. Stop the reaction by adding 5µl of 3% phosphoric acid.
- 10. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
- 11. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
- 12. Wash the filtermat once for 2 minutes with methanol.
- 13. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
- 14. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.



Certificate of Analysis

MLCK Sequence Information

Protein	Human MLCK
<u>Tags</u>	N-terminal 6His
Native sequence	G31 of the recombinant protein is equivalent to G1425 of human MLCK
Accession number	GenBank NM_053025

Recombinant MLCK amino acid sequence:

МЅҮҮННННН	DYDIPTTENL	YFQGAMDPEF	GEKPEEPKDE	VEVSDDDEKE	PEVDYRTVTI
NTEQKVSDFY	DIEERLGSGK	FGQVFRLVEK	KTRKVWAGKF	FKAYSAKEKE	NIRQEISIMN
CLHHPKLVQC	VDAFEEKANI	VMVLEIVSGG	ELFERIIDED	FELTERECIK	YMRQISEGVE
YIHKQGIVHL	DLKPENIMCV	NKTGTRIKLI	DFGLARRLEN	AGSLKVLFGT	PEFVAPEVIN
YEPIGYATDM	WSIGVICYIL	VSGLSPFMGD	NDNETLANVT	SATWDFDDEA	FDEISDDAKD
FISNLLKKDM	KNRLDCTQCL	QHPWLMKDTK	NMEAKKLSKD	RMKKYMARRK	WQKTGNAVRA
IGRLSSMAMI	SGLSGRK				
	MSYYHHHHHH NTEQKVSDFY CLHHPKLVQC YIHKQGIVHL YEPIGYATDM FISNLLKKDM IGRLSSMAMI	MSYYHHHHHH DYDIPTTENL NTEQKVSDFY DIEERLGSGK CLHHPKLVQC VDAFEEKANI YIHKQGIVHL DLKPENIMCV YEPIGYATDM WSIGVICYIL FISNLLKKDM KNRLDCTQCL IGRLSSMAMI SGLSGRK	MSYYHHHHHH DYDIPTTENL YFQGAMDPEF NTEQKVSDFY DIEERLGSGK FGQVFRLVEK CLHHPKLVQC VDAFEEKANI VMVLEIVSGG YIHKQGIVHL DLKPENIMCV NKTGTRIKLI YEPIGYATDM WSIGVICYIL VSGLSPFMGD FISNLLKKDM KNRLDCTQCL QHPWLMKDTK IGRLSSMAMI SGLSGRK	MSYYHHHHHH DYDIPTTENL YFQGAMDPEF GEKPEEPKDE NTEQKVSDFY DIEERLGSGK FGQVFRLVEK KTRKVWAGKF CLHHPKLVQC VDAFEEKANI VMVLEIVSGG ELFERIIDED YIHKQGIVHL DLKPENIMCV NKTGTRIKLI DFGLARRLEN YEPIGYATDM WSIGVICYIL VSGLSPFMGD NDNETLANVT FISNLLKKDM KNRLDCTQCL QHPWLMKDTK NMEAKKLSKD IGRLSSMAMI SGLSGRK	MSYYHHHHH DYDIPTTENL YFQGAMDPEF GEKPEEPKDE VEVSDDDEKE NTEQKVSDFY DIEERLGSGK FGQVFRLVEK KTRKVWAGKF FKAYSAKEKE CLHHPKLVQC VDAFEEKANI VMVLEIVSGG ELFERIIDED FELTERECIK YIHKQGIVHL DLKPENIMCV NKTGTRIKLI DFGLARRLEN AGSLKVLFGT YEPIGYATDM WSIGVICYIL VSGLSPFMGD NDNETLANVT SATWDFDDEA FISNLLKKDM KNRLDCTQCL QHPWLMKDTK NMEAKKLSKD RMKKYMARRK IGRLSSMAMI SGLSGRK

Recombinant MLCK nucleotide sequence:

1	atgtcgtact	accatcacca	tcaccatcac	gattacgata	tcccaacgac	cgaaaacctg
61	tattttcagg	gcgccatgga	tccggaattc	ggagagaaac	ctgaagagcc	gaaggatgaa
121	gtggaggtgt	cagatgatga	tgagaaggag	cccgaggttg	attaccggac	agtgacaatc
181	aatactgaac	aaaaagtatc	tgacttctac	gacattgagg	agagattagg	atctgggaaa
241	tttggacagg	tctttcgact	tgtagaaaag	aaaactcgaa	aagtctgggc	agggaagttc
301	ttcaaggcat	attcagcaaa	agagaaagag	aatatccggc	aggagattag	catcatgaac
361	tgcctccacc	accctaagct	ggtccagtgt	gtggatgcct	ttgaagaaaa	ggccaacatc
421	gtcatggtcc	tggagatcgt	gtcaggaggg	gagctgtttg	agcgcatcat	tgacgaggac
481	tttgagctga	cggagcgtga	gtgcatcaag	tacatgcggc	agatctcgga	gggagtggag
541	tacatccaca	agcagggcat	cgtgcacctg	gacctcaagc	cggagaacat	catgtgtgtc
601	aacaagacgg	gcaccaggat	caagctcatc	gactttggtc	tggccaggag	gctggagaac
661	gcggggtctc	tgaaggtcct	ctttggcacc	ccagaatttg	tggctcctga	agtgatcaac
721	tatgagccca	tcggctacgc	cacagacatg	tggagcatcg	gggtcatctg	ctacatccta
781	gtcagtggcc	tttcccctt	catgggagac	aacgataacg	aaaccttggc	caacgttacc
841	tcagccacct	gggacttcga	cgacgaggca	ttcgatgaga	tctccgacga	tgccaaggat
901	ttcatcagca	atctgctgaa	gaaagatatg	aaaaaccgcc	tggactgcac	gcagtgcctt
961	cagcatccat	ggctaatgaa	agataccaag	aacatggagg	ccaagaaact	ctccaaggac
1021	cggatgaaga	agtacatggc	aagaaggaaa	tggcagaaaa	cgggcaatgc	tgtgagagcc
1081	attqqaaqac	tgtcctctat	ggcaatgatc	tcagggctca	gtggcaggaa	ataa

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.